Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study

Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study

Abstract Background Repaglinide is widely prescribed to reduce postprandial hyperglycemia and elevated glycated hemoglobin (HbA1c) levels associated with type 2 diabetes, and clopidogrel is a thienopyridine antiplatelet agent and widely used in cardiovascular and cerebrovascular diseases. It has bee...

Full description

Bibliographic Details
Main Authors: Yuuki Akagi, Akiko Iketaki, Haruna Kimura, Yuki Matsudaira, Takami Yoshida, Takahiro Nishimura, Yohei Kawano, Yasunari Mano, Erina Shigematsu, Makoto Ujihara
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Repaglinide
Clopidogrel
Drug-drug interaction
Hypoglycemia
Cytochrome P450 2C8
Mitiglinide
Online Access:http://link.springer.com/article/10.1186/s40780-020-00159-7

Internet

http://link.springer.com/article/10.1186/s40780-020-00159-7

Similar Items